Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14641302 | 0.94 | CASP3 (0.53) | CASP3HRH3MMEACEPREP | |
| SCHEMBL14603134 | 0.94 | CASP3 (0.53) | CASP3HRH3MMEACEPREP | |
| SCHEMBL6599837 | 0.83 | CASP3 (0.66) | CASP3MMEACEKCNH2TACR2 | |
| SCHEMBL14603133 | 0.82 | CASP3 (0.64) | CASP3MMEACE | |
| SCHEMBL14641301 | 0.82 | CASP3 (0.64) | CASP3MMEACE | |
| SCHEMBL5650545 | 0.82 | CASP3 (0.64) | CASP3MMEACE | |
| SCHEMBL6601810 | 0.81 | CASP3 (0.68) | CASP3MMEACEKCNH2TACR2 | |
| SCHEMBL14603128 | 0.80 | CASP3 (0.61) | CASP3MMEACE | |
| SCHEMBL14603132 | 0.80 | CASP3 (0.61) | CASP3MMEACE | |
| SCHEMBL14641489 | 0.80 | CASP3 (0.61) | CASP3MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1358178-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | Bristol-Myers Squibb Company (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| WO-2002060894-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | CASP3 1524/4885HRH3 664/4885MME 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.